Alkem Laboratories (NSE:ALKEM) Total Liabilities: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ALKEM Alkem Laboratories Ltd NSE:ALKEM
97 GF Score
Price ₹5,374.00
GF Value ₹6,146.47
Valuation Modestly Undervalued
View Full Analysis

What is Alkem Laboratories Total Liabilities?

Alkem Laboratories NSE:ALKEM +0.11% 97 Total Liabilities is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:ALKEM with a GF Score™ of 97/100 and a GF Value™ of ₹6,146.47 (Modestly Undervalued).

Alkem Laboratories's Total Liabilities for the quarter that ended in Jun. 2026 was ₹0 Mil.

Alkem Laboratories's quarterly Total Liabilities increased from Dec. 2025 (₹0.00 Mil) to Mar. 2026 (₹65,240.40 Mil) but then declined from Mar. 2026 (₹65,240.40 Mil) to Jun. 2026 (₹0.00 Mil).

Alkem Laboratories's annual Total Liabilities increased from Mar. 2024 (₹48,605.00 Mil) to Mar. 2025 (₹52,574.70 Mil) and increased from Mar. 2025 (₹52,574.70 Mil) to Mar. 2026 (₹65,240.40 Mil).

Alkem Laboratories Total Liabilities Historical Data

* Premium members only.

The historical data trend for Alkem Laboratories's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alkem Laboratories Total Liabilities Chart

Alkem Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 52,218.60 43,216.50 48,605.00 52,574.70 65,240.40

Alkem Laboratories Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 64,765.20 0.00 65,240.40 0.00
NSE:ALKEM
97GF Score
Alkem Laboratories Ltd NSE:ALKEM
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alkem Laboratories Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Alkem Laboratories's Total Liabilities for the fiscal year that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=47827+(8692.3+4409
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+4312.1+0)
=65,240

Total Liabilities=Total Assets (A: Mar. 2026 )-Total Equity (A: Mar. 2026 )
=208729.7-143489.3
=65,240

Alkem Laboratories's Total Liabilities for the quarter that ended in Jun. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=N/A

Total Liabilities=Total Assets (Q: Jun. 2026 )-Total Equity (Q: Jun. 2026 )
=N/A-N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of ₹0 Mil mean?
Alkem Laboratories (NSE:ALKEM) has a Total Liabilities of ₹0 Mil as of Jun. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Alkem Laboratories and its competitors.
Is Alkem Laboratories' Total Liabilities too high?
Alkem Laboratories' current Total Liabilities is ₹0 Mil. Overall, Alkem Laboratories has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alkem Laboratories' Total Liabilities compare to ZTS?
Alkem Laboratories' Total Liabilities of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Alkem Laboratories and its competitors. Alkem Laboratories's current Total Liabilities is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alkem Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Alkem Laboratories (NSE:ALKEM) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹6,146.47, compared to a current price of ₹5,374.00 — trading 12.6% below its estimated fair value. The current Total Liabilities is ₹0 Mil. Alkem Laboratories' overall GF Score™ is 97/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Alkem Laboratories (NSE:ALKEM), the current Total Liabilities is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alkem Laboratories (NSE:ALKEM) Overvalued in 2026?

Based on GuruFocus' analysis, Alkem Laboratories stock appears to be undervalued. The current stock price of ₹5,374.00 is trading 12.6% below its estimated GF Value™ of ₹6,146.47. GuruFocus considers Alkem Laboratories to be Modestly Undervalued.

Key valuation signals for NSE:ALKEM:

  • Total Liabilities: ₹0 Mil
  • GF Value™: ₹6,146.47 vs. price of ₹5,374.00 (12.6% below fair value)
  • GF Score™: 97/100

No single metric tells the full story. See the NSE:ALKEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alkem Laboratories Business Description

Other Exchanges 539523:India
Address Senapati Bapat Marg, Alkem House, Devashish Building, Lower Parel, Mumbai, MH, IND, 400 013
Alkem Laboratories Ltd is an Indian pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals in acute and chronic therapeutic areas, such as anti-infective, pain and analgesics, vitamins/minerals/nutrients, cardiac and Diabetology, Gynecology, neuro/central nervous system, dermatology, anti-diabetes, anti-osteoporosis, cardiovascular, and muscle relaxants, which are marketed in Indian and International markets. It operates through the pharmaceutical business segment.
97GF Score

Get the complete analysis for NSE:ALKEM

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹5,374.00
Price
₹6,146.47
GF Value